°íÀ±È£(Ko Yoon-Ho) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
À̸í¾Æ(Lee Myung-Ah) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
È«¿µ¼±(Hong Yeong-Seon) - ¼ººó¼¾Æ®º´¿ø Æó¾Ï¼¾ÅÍ
ÀÌ°æ½Ä(Lee Kyung-Shik) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÚÇöÁø(Park Hyun-Jin) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¿µ»óÀÇÇб³½Ç
À¯ÀÌ·É(Yoo Ie-Ryung) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ °³²¼º¸ðº´¿ø ÇÙÀÇÇаú
±è¿¬½Ç(Kim Yeon-Sil) - °¡Å縯´ëÇб³ °³²¼º¸ðº´¿ø ¹æ»ç¼±Á¾¾çÇаú
±è¿µ±Õ(Kim Young-Kyoon) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç È£Èí±â³»°ú
Á¶°ÇÇö(Jo Keon-Hyun) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ °³²¼º¸ðº´¿ø ÈäºÎ¿Ü°ú
¿Õ¿µÇÊ(Wang Young-Pil) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÈäºÎ¿Ü°úÇб³½Ç
À̱³¿µ(Lee Kyo-Young) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÓ»óº´¸®Çб³½Ç
°ÁøÇü(Kang Jin-Hyoung) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Background : Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week chedule, yet there is significant toxicity with this therapy. Therefore, a weekly schedule has been explored in several previous trials. In this retrospective study, we compared the efficacy and safety of a weekly schedule and a 3-week schedule of docetaxel monotherapy in a second-line setting.
Methods : Docetaxel was administered as 75 mg/m2 on day 1 every 3 weeks or as 37.5 mg/m2 on day 1 and 8 every 3 weeks until disease progression or severe toxicity developed.
Results : From October 2003 to March 2006, a total of 37 patients received docetaxel monotherapy and 36 patients could be valuated. A total of 135 cycles were administered and then evaluated. The median overall survival was 13.3 months (95% confidence interval: 6.3¢¦20.3) for the weekly schedule and 10.7 months (95%confidence interval: 8.3¢¦13.0) for the 3-week schedule (p=0.41). The median time to progression was 3.0 months (95% confidence interval: 1.9¢¦4.0) and 2.8 months (95% confidence interval: 1.0¢¦4.6), respectively (p=0.41). The response rate was 16.7% for the weekly schedule and 21.1% for the 3-week schedule. The major form of hematologic toxicity was grade 3-4 neutropenia (3-week: 38.9%, weekly: 9.5%). The non-hematologic toxicities were similar between the two schedules. There were no treatment-related deaths.
Conclusions : A docetaxel weekly schedule was very tolerable and it had comparable activity to that of the 3-week docetaxel schedule. Considering the efficacy and tolerability, a docetaxel weekly schedule can be an alternative schedule for the standard treatment of NSCLC in a second-line setting
Å°¿öµå
Carcinoma, Non-Small-Cell Lung, Docetaxel, Chemotherapy
KMID :
0338420070220030178
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
A docetaxel weekly schedule was very tolerable and it had comparable activity to that of the 3-week docetaxel schedule. Considering the efficacy and tolerability, a docetaxel weekly schedule can be an alternative schedule for the standard treatment of NSCLC in a second-line setting